Amorfrutins are potent antidiabetic dietary natural products

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 19, 2012, Pages 7257-7262

  Weidner, Christopher ^a,b   De Groot, Jens C ^c   Prasad, Aman ^d   Freiwald, Anja ^a   Quedenau, Claudia ^a   Kliem, Magdalena ^a   Witzke, Annabell ^a   Kodelja, Vitam ^a   Han, Chung Ting ^a   Giegold, Sascha ^e   Baumann, Matthias ^e   Klebl, Bert ^e   Siems, Karsten ^f   Müller Kuhrt, Lutz ^f   Schürmann, Annette ^g   Schülerg, Rita ^g   Pfeiffer, Andreas F H ^g   Schroeder, Frank C ^d   Büssow, Konrad ^c   Sauer, Sascha ^a  

^a MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d United States Department of Agriculture Agricultural Research Service and Boyce Thompson Institute for Plant Research   (United States)

^e Lead Discovery Center GmbH   (Germany)

^f ANALYTICON DISCOVERY GMBH   (Germany)

^g GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Compound screening; Nuclear receptors; Nutrition; Organic synthesis; X ray structure

Indexed keywords

AMORFRUTIN 1; AMORFRUTIN 2; AMORFRUTIN 3; AMORFRUTIN 4; ANTIDIABETIC AGENT; GLYCYRRHIZA EXTRACT; NP 003520; NP 003521; NP 006430; NP 009525; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLYCYRRHIZA; INSULIN RESISTANCE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL;

3T3-L1 CELLS; ANIMALS; BIOLOGICAL AGENTS; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; FABACEAE; GENE EXPRESSION; GLYCYRRHIZA; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; OBESITY; PPAR GAMMA; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALICYLIC ACIDS;

AMORPHA FRUTICOSA; GLYCYRRHIZA; MUS;

EID: 84860795758     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1116971109     Document Type: Article

References (39)

1. Smyth S, Heron A (2006) Diabetes and obesity: the twin epidemics. Nat Med 12:75-80. (Pubitemid 43050080)
2. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846. (Pubitemid 46024990)
3. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123:993-999.
4. Huang TH, Kota BP, Razmovski V, Roufogalis BD (2005) Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol 96:3-14. (Pubitemid 40260842)
5. Hontecillas R, O'Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J (2009) Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J Am Coll Nutr 28:184-195.
6. Guri AJ, Hontecillas R, Si H, Liu D, Bassaganya-Riera J (2007) Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets. Clin Nutr 26:107-116. (Pubitemid 46179115)
7. Anonymous (2010) Regulators restrict Avandia in the US and suspend it in the EU. Nat Rev Drug Discov 9:828-828.
8. Rosen CJ (2010) Revisiting the rosiglitazone story-lessons learned. N Engl J Med 363:803-806.
9. Argmann CA, Cock TA, Auwerx J (2005) Peroxisome proliferator-activated receptor gamma: the more the merrier? Eur J Clin Invest 35:82-92 discussion 80.
10. Cock TA, Houten SM, Auwerx J (2004) Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep 5:142-147. (Pubitemid 38401192)
11. Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950-964. (Pubitemid 39534319)
12. Choi JH, et al. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466:451-456.
13. Jones D (2010) Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 9:668-669.
14. Li JW, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325:161-165.
15. Muller M, Kersten S (2003) Nutrigenomics: goals and strategies. Nat Rev Genet 4:315-322. (Pubitemid 36389536)
16. Cho N, Momose Y (2008) Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem 8:1483-1507.
17. Li P, et al. (2011) Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 147:815-826.
18. Nolte RT, et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143. (Pubitemid 28425645)
19. Cronet P, et al. (2001) Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9:699-706. (Pubitemid 32772892)
20. Bruning JB, et al. (2007) Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15:1258-1271. (Pubitemid 47539157)
21. Berger JP, et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator- activated protein [gamma] selective modulator. Mol Endocrinol 17:662-676. (Pubitemid 36403578)
22. Schupp M, et al. (2005) Molecular characterization of new selective peroxisome proliferator- activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 54:3442-3452. (Pubitemid 43334334)
23. Fischer JJ, et al. (2011) Dasatinib, imatinib and staurosporine capture compounds - Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS). J Proteomics 10:160-168.
24. Ong SE, et al. (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci USA 106:4617-4622.
25. Dat NT, et al. (2008) Phenolic constituents of Amorpha fruticosa that inhibit NF-kappaB activation and related gene expression. J Nat Prod 71:1696-1700.
26. Lamb J, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935. (Pubitemid 44497995)
27. Larsen PJ, et al. (2003) Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes 52:2249-2259. (Pubitemid 37059494)
28. Alegret M, et al. (1994) Relationship between plasma lipids and palmitoyl-CoA hydrolase and synthetase activities with peroxisomal proliferation in rats treated with fibrates. Br J Pharmacol 112:551-556. (Pubitemid 24172899)
29. Doshi LS, Brahma MK, Bahirat UA, Dixit AV, Nemmani KV (2010) Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents. Expert Opin Inv Drug 19:489-512.
30. Ryan KK, et al. (2011) A role for central nervous system PPAR-gamma in the regulation of energy balance. Nat Med 17:623-626.
31. Lu M, et al. (2011) Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 17:618-622.
32. Marchesini G, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850. (Pubitemid 33641605)
33. Kulozik P, et al. (2011) Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab 13:389-400.
34. Spiegelman BM, Frank M, Green H (1983) Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerophosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J Biol Chem 258:10083-10089.
35. Artis DR, et al. (2009) Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci USA 106:262-267.
36. Hotamisligil GS, Shargill NS, Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91. (Pubitemid 23036092)
37. Kuda O, et al. (2009) Prominent role of liver in elevated plasma palmitoleate levels in response to rosiglitazone in mice fed high-fat diet. J Physiol Pharmacol 60:135-140.
38. Rizzo G, Fiorucci S (2006) PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 6:421-427.
39. Argmann C, et al. (2009) Ppargamma2 is a key driver of longevity in the mouse. PLoS Genet 5:e1000752.